Development of Inhalable Nanostructured Lipid Carriers for Ciprofloxacin for Noncystic Fibrosis Bronchiectasis Treatment

PURPOSE: Ciprofloxacin (CIP) has poor lung targeting after oral inhalation. This study developed optimized inhalable nanostructured lipid carriers (NLCs) for CIP to enhance deposition and accumulation in deeper parts of the lungs for treatment of noncystic fibrosis bronchiectasis (NCFB). METHODS: NL...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Int J Nanomedicine
Main Authors: Almurshedi, Alanood S, Aljunaidel, Hessah A, Alquadeib, Bushra, Aldosari, Basmah N, Alfagih, Iman M, Almarshidy, Salma S, Eltahir, Eram K D, Mohamoud, Amany Z
Formato: Artigo
Idioma:Inglês
Publicado em: Dove 2021
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8012696/
https://ncbi.nlm.nih.gov/pubmed/33814907
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IJN.S286896
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados